Orbimed Advisors LLC Bellus Health Inc. Transaction History

Orbimed Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$7.14 - $8.53 $2.86 Million - $3.41 Million	400,000 Added 8.49%	5,108,900 $36.8 Million
Q4 2022 Feb 14, 2023	BUY	$8.22 - $10.76 $608,280 - $796,240	74,000 Added 1.6%	4,708,900 $38.7 Million
Q3 2022 Nov 14, 2022	BUY	$8.95 - $12.0 $28.5 Million - $38.2 Million	3,180,100 Added 218.59%	4,634,900 $49 Million
Q4 2021 Feb 14, 2022	SELL	$5.26 - $8.3 $5.26 Million - $8.3 Million	-1,000,000 Reduced 40.74%	1,454,800 $11.7 Million
Q3 2021 Nov 15, 2021	SELL	$2.7 - $6.64 $4.05 Million - $9.96 Million	-1,500,000 Reduced 37.93%	2,454,800 $15 Million
Q1 2021 May 17, 2021	SELL	$3.03 - $4.58 $711,422 - $1.08 Million	-234,793 Reduced 5.6%	3,954,800 $15.1 Million
Q4 2020 Feb 16, 2021	SELL	$2.27 - $3.3 $2.15 Million - $3.13 Million	-947,623 Reduced 18.45%	4,189,593 $12.6 Million
Q2 2020 Aug 14, 2020	SELL	$8.88 - $11.15 $16.8 Million - $21.1 Million	-1,888,616 Reduced 26.88%	5,137,216 $53 Million
Q3 2019 Nov 14, 2019	BUY	$6.24 - $8.84 $43.8 Million - $62.1 Million	7,025,832 New	7,025,832 $45.1 Million

128K

Ticker BLU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,793,000
Description
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. Th...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.